Medications for Hemophilia B

7 results

  • alhemo

    (concizumab)
    Novo Nordisk
    Alhemo is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency with inhibitors) and hemophilia B (factor IX deficiency with inhibitors).

  • alprolix

    (Coagulation Factor IX (Recombinant), Fc Fusion Protein)
    Bioverativ Therapeutics Inc.
    ALPROLIX is indicated for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis in adults and children with hemophilia B. It is not intended for inducing immune tolerance.

  • benefix

    (coagulation factor ix (recombinant))
    Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
    BeneFIX® is indicated for adults and children with hemophilia B for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce bleeding frequency. It is not intended for immune tolerance induction in hemophilia B patients.

  • beqvez

    (fidanacogene elaparvovec-dzkt)
    Pfizer Laboratories Div Pfizer Inc
    BEQVEZ is a gene therapy for adults with moderate to severe hemophilia B, indicated for those on factor IX prophylaxis, experiencing life-threatening hemorrhages or serious spontaneous bleeding, and without neutralizing antibodies to AAVRh74var capsid, based on FDA-approved diagnostics.

  • hympavzi

    (marstacimab-hncq)
    Pfizer Laboratories Div Pfizer Inc
    HYMPAVZI is used for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency), both without inhibitors.

  • profilnine

    (factor ix complex)
    GRIFOLS USA, LLC
    Profilnine (Factor IX Complex) is indicated for preventing and controlling bleeding in patients with factor IX deficiency (hemophilia B). It is not indicated for factor VII deficiency treatment.

  • sevenfact

    (Coagulation Factor VIIa Recombinant Human)
    Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme (LFB S.A.)
    SEVENFACT is indicated for treating and controlling bleeding episodes in adults and adolescents (12 years and older) with hemophilia A or B with inhibitors. It is not indicated for patients with congenital Factor VII deficiency.